Previous 10 | Next 10 |
HOLON, Israel , Sept. 19, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced progress in its ongoing Phase 1 clinical study evaluating COM701, a first-in-class therapeuti...
Compugen Ltd. (CGEN) Q2 2019 Results Earnings Conference Call August 5, 2019, 08:30 AM ET Company Participants Elana Holzman - Director of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Henry Adewoye - Chief Medical Office...
IPic Entertainment (NASDAQ: IPIC ) -57% after bankruptcy filing . More news on: iPic Entertainment Inc., GlycoMimetics, Inc., Cars.com Inc., Stocks on the move, Read more ...
HOLON, Israel , Aug. 5, 2019 /PRNewswire/ -- Compugen Ltd. ( Nasdaq: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the second quarter ended June 30, 2019 . "We continue...
HOLON, ISRAEL , July 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its second quarter 2019 financial results on Monday, A...
The USPTO has granted Compugen (NASDAQ: CGEN ) a new Patent No. 10,351,625, titled "Anti-PVRIG Antibodies and Methods of Use," covering method of use of COM701, a therapeutic antibody targeting PVRIG, in combination with anti-PD-1 antibodies. More news on: Compugen Ltd., Health...
HOLON, Israel , July 16, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent covering method of use...
HOLON, Israel , June 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targe...
HOLON, Israel , May 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that Anat Cohen-Dayag , PhD, President and CEO, will present a corporate overview an...
Compugen Ltd. (CGEN) Q1 2019 Results Earnings Conference Call May 20, 2019, 08:30 AM ET Company Participants Elana Holzman - Director, IR and Corporate Communications Anat Cohen-Dayag - President and CEO Ari Krashin - CFO and COO Henry Adewoye - CMO Conference Call Participa...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...